General Metadata
Title
Značaj galektina-1 kao prognostičkog faktora u lečenju klasičnog Hočkinovog limfoma
Creator
Simonović, Olivera B. 1971-
Copyright date
2017
Object Links
Permanent link
Full text preview
Download link
Select license
Autorstvo-Nekomercijalno-Bez prerade 3.0 Srbija (CC BY-NC-ND 3.0)
License description
Dozvoljavate samo preuzimanje i distribuciju dela, ako/dok se pravilno naznačava ime autora, bez ikakvih promena dela i bez prava komercijalnog korišćenja dela. Ova licenca je najstroža CC licenca. Osnovni opis Licence: http://creativecommons.org/licenses/by-nc-nd/3.0/rs/deed.sr_LATN. Sadržaj ugovora u celini: http://creativecommons.org/licenses/by-nc-nd/3.0/rs/legalcode.sr-Latn
Language
Serbian
Cobiss-ID
1025977325
Academic metadata
Theses Type
Doktorska disertacija
description
Datum odbrane: 27.2.2018.
Other responsibilities
mentor
Marjanović, Goran
član komisije
Mačukanović-Golubović, Lana
član komisije
Jevtović-Stoimenov, Tatjana
član komisije
Mihaljević, Biljana
Academic Expertise
Medicinske nauke
University
Univerzitet u Nišu
Faculty
Medicinski fakultet
Group
Katedra za internu medicinu
Other Theses Metadata
Abstract (en)
In classical Hodgkin’s lymphoma (cHL) the existing prognostic scoring systems do not include markers that adequately reflect the interaction of malignant Hodgkin and Reed-Sternberg (HRS) cells and tumor environment. The research objective is to determine the relationship between serum Galectin-1 (Gal-1) and soluble CD163 (sCD163) and the clinical status of patients with cHL, with special emphasis on the presence of relapse, progression, or resistance to the therapy applied. The research included 79 patients. Of this number, 63 were patients with cHL, and the control group consisted of 16 healthy volunteers. The study group of 63 patients with cHL included a subgroup of newly diagnosed patients without therapy, newly diagnosed patients with therapy, patients with relapse and progression of the disease, and primary refractory patients during 2014 and 2015. Analysis of the levels of sCD163 and sGal-1 within a group of patients suffering from cHL has shown that the values of both molecules were higher in relapsed patients and the subgroup with progressive disease comparing the subgroup of newly diagnosed patients without therapy or patients with therapy onset. Determination of Gal-1 and sCD163 levels is simple and reliable analysis that can contribute to the identification of high-risk patients with cHL, and deserves inclusion in current prognostic scoring systems.